Cimaglermin alfa

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameCimaglermin alfa
Drug Alias NameNeuregulin 1β3Neuregulin 1 proteinGlial growth factor 2Recombinant human glial growth factor-2 (rhGGF 2)NRG1 protein +[9] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionEpidermal growth factor receptor erbB1 modulators
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsHeart Failure
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesLudwig Institute For Cancer Research
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAcorda Therapeutics
Active IndicationsN/A
Inactive IndicationsHeart Failure

Other Information

ATC CodeN/A
Related LinksN/A